Eisai rufinamide NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Eisai is seeking two indications for its anti-epileptic rufinamide: adjunctive therapy for Lennox-Gastaut syndrome in children ages four and up and adjunctive therapy for partial-onset seizures with and without secondary generalization in adults and adolescents ages 12 and over. The firm submitted the NDA for the triazole derivative Sept. 9, putting a standard review deadline at July 9, 2006. The two pivotal trials supporting the indications were conducted by innovator Novartis. Rufinamide is "structurally distinct from currently approved [anti-epileptic drugs]," Eisai notes. The agent was granted orphan status for Lennox-Gastaut in October 2004...
You may also be interested in...
Eisai Rufinamide Electronic Resubmission Aims To Make NDA More Accessible
Formatting issues with Eisai's original rufinamide anti-epilepsy NDA could result in a more than two-month delay in approval
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.